Precision Dosing: The Clinical Pharmacology of Goldilocks

Affiliations

¹ Pharma Research & Development (pRED), Roche Innovation Center, Basel, Switzerland.
² Pfizer Global Research, Groton, Connecticut, USA.
³ Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.

Editorial

Richard W Peck et al. Clin Pharmacol Ther. 2021 Jan.

. 2021 Jan;109(1):11-14.

doi: 10.1002/cpt.2112.

¹ Pharma Research & Development (pRED), Roche Innovation Center, Basel, Switzerland.
² Pfizer Global Research, Groton, Connecticut, USA.
³ Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.

No abstract available

References

1. Stout, S.M. et al. Interpretation of cytochrome P‐450 inhibition and induction effects from clinical data: current standards and recommendations for implementation. Clin. Pharmacol. Ther. 109, 82–86 (2021).
1. Yang, X., Pfuma Fletcher, E., Huang, S.M., Zineh, I. & Madabushi, R. Regulatory efforts to facilitate evaluation and clinical management of drug‐drug interaction risks. Clin. Pharmacol. Ther. 109, 42–46 (2021).
1. Achour, B. et al. Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters. Clin. Pharmacol. Ther. 109, 222–232 (2021).
1. Zamek‐Gliszczynski, M.J. et al. Intestinal P‐gp and putative hepatic OATP1B induction: international transporter consortium perspective on drug development implications. Clin. Pharmacol. Ther. 109, 55–64 (2021).
1. Liu, M. et al. A tutorial for pharmacogenomics implementation through end‐to‐end clinical decision support based on ten years of experience from PREDICT. Clin. Pharmacol. Ther. 109, 101–115 (2021).